P2–390: GEPT extract prevents beta‐amyloid‐deposition–induced synaptic dysfunction in APPV717I transgenic mice, possibly by adjusting the expression of CaMKII and CaN

Is the Combination/Multi-target Therapy a New Promise for Alzheimer's Disease?

“…Preliminary clinical studies of GAPT in treating amnestic mild cognitive impairment showed that it can significantly improved the cognitive function of patients with early-stage AD, amnestic mild cognitive impairment (MCI) [29,30]. In animal studies, GAPT extract can markedly enhance learning and memory of AD rat models induced by hippocampal injection of Aβ1-42 peptide or intravenous injection of Aβ1-40 peptide or STZ, as well as APPV717I transgenic mice and APPswe/PS1dE9 transgenic mice [31][32][33][34]. Evidences showed that GAPT may inhibit γ-secretase (presenilin-1) and promote insulin degrading enzyme and neprilysin, thus reduce Aβ levels in the brain of APPV717I transgenic mice.…”